Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Parsaclisib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Incyte stops PhIII trial for PI3K inhibitor after primary endpoint failure
    Incyte stops PhIII trial for PI3K inhibitor after primary endpoint failure

    07 Mar 2023

    // ENDPTS

    https://endpts.com/incyte-stops-phiii-trial-for-pi3k-inhibitor-after-primary-endpoint-failure/

    ENDPTS
    07 Mar 2023
    Share Share
    Incyte to discontinue late-stage trial for bone marrow cancer drug combination
    Incyte to discontinue late-stage trial for bone marrow cancer drug combination

    04 Mar 2023

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/incyte-discontinue-late-stage-trial-bone-marrow-cancer-drug-combination-2023-03-03/

    REUTERS
    04 Mar 2023
    Share Share
    Incyte Provides Update on PIII LIMBER-304 Study of Parsaclisib and Ruxolitinib
    Incyte Provides Update on PIII LIMBER-304 Study of Parsaclisib and Ruxolitinib

    03 Mar 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230303005316/en

    BUSINESSWIRE
    03 Mar 2023
    Share Share
    Innovent Announces the NMPA in China Has Granted Priority Review to Parsaclisib
    Innovent Announces the NMPA in China Has Granted Priority Review to Parsaclisib

    05 Jan 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/innovent-announces-the-national-medical-products-administration-in-china-has-accepted-and-granted-priority-review-designation-to-the-new-drug-application-for-parsaclisib-pi3k-inhibitor-for-the-treatment-of-relapsed-or-refractor-301715196.html

    PR NEWSWIRE
    05 Jan 2023
    Share Share
    Incyte Announces Data from LIMBER Studies Evaluating Combination Treatments
    Incyte Announces Data from LIMBER Studies Evaluating Combination Treatments

    10 Dec 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20221210005030/en

    BUSINESSWIRE
    10 Dec 2022
    Share Share
    Incyte pulls approval filing, following Gilead out of the exitIn
    Incyte pulls approval filing, following Gilead out of the exitIn

    27 Jan 2022

    // N.P. Taylor FIERCEBIOTECH

    https://www.fiercebiotech.com/biotech/incyte-pulls-fda-filing-for-cancer-drug-approval-over-confirmatory-study-following-gilead

    N.P. Taylor FIERCEBIOTECH
    27 Jan 2022
    Share Share